SONOMA PHARMACEUTICALS INC
SNOANASDAQ🏆 #3711 by market capUS Equity
$1.39▲ $0.10 (+6.92%)
Live1h—
24h▲ 6.9%
7d▲ 13.9%
14d▲ 20.9%
30d▲ 10.3%
1y▼ 54.4%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
+36.7%
High Growth
📊Gross Margin
38.0%
Healthy
💵FCF Margin
5.4%
Moderate
⚖️P/S Ratio
0.3x
Cheap
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $1.37 – $1.41
- 52-Week Range
- $0.85 – $6.92
- Volume
- $2.32B
- Avg Volume
- $1.97B
- Shares Outstanding
- 4.8M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $20M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-1.89
- Dividend Yield
- —
Why Investors Own SNOA
- ✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$20M▼ −7.6% YoY
Gross Margin (TTM)
72.6%▲ +0.9% YoY
Operating Income (TTM)
$5M▼ −7.6% YoY
Free Cash Flow (TTM)
$3M▼ −7.6% YoY
About SONOMA PHARMACEUTICALS INC
A company profile for SONOMA PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$1.39
▼ −0.2% Downside
High Target$1.60
Low Target$1.19
Based on 14 analysts
Latest News & Updates
🚀
Barron’s·2h ago
SONOMA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift SNOA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
SONOMA PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.